ANO5 sirna

ANO5 siRNA (Human)

Cat. Num. AAA828703

• Gene Names: ANO5; GDD1; LGMD2L; TMEM16E
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: ANO5; ANO5 siRNA (Human); GDD1; TMEM16E; Anoctamin-5; Gnathodiaphyseal dysplasia 1 protein; Transmembrane protein 16E; ANO5 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: ANO5 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 912

• Applicable Applications for ANO5 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ANO5 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for ANO5 sirna

siRNA to inhibit ANO5 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 218081589
• NCBI GeneID: 203859
• NCBI Accession #: NP_001136121.1
• NCBI GenBank Nucleotide #: NM_001142649.1
• UniProt Accession #: Q75V66
• Molecular Weight: 107,188 Da
• NCBI Official Full Name: anoctamin-5 isoform b
• NCBI Official Synonym Full Names: anoctamin 5
• NCBI Official Symbol: ANO5
• NCBI Official Synonym Symbols: GDD1; LGMD2L; TMEM16E
• NCBI Protein Information: anoctamin-5
• UniProt Protein Name: Anoctamin-5
• Protein Family: Anoctamin
• UniProt Gene Name: ANO5
• UniProt Synonym Gene Names: GDD1; TMEM16E
• UniProt Entry Name: ANO5_HUMAN

NCBI Description

This gene encodes a member of the anoctamin family of transmembrane proteins. The encoded protein is likely a calcium activated chloride channel. Mutations in this gene have been associated with gnathodiaphyseal dysplasia. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]

Uniprot Description

ANO5: May act as a calcium-activated chloride channel. Defects in ANO5 are the cause of gnathodiaphyseal dysplasia (GDD); also known as osteogenesis imperfecta with unusual skeletal lesions or gnathodiaphyseal sclerosis. GDD is a rare skeletal syndrome characterized by bone fragility, sclerosis of tubular bones, and cemento-osseous lesions of the jawbone. Patients experience frequent bone fractures caused by trivial accidents in childhood; however the fractures heal normally without bone deformity. The jaw lesions replace the tooth-bearing segments of the maxilla and mandible with fibrous connective tissues, including various amounts of cementum-like calcified mass, sometimes causing facial deformities. Patients also have a propensity for jaw infection and often suffer from purulent osteomyelitis-like symptoms, such as swelling of and pus discharge from the gums, mobility of the teeth, insufficient healing after tooth extraction and exposure of the lesions into the oral cavity. Defects in ANO5 are the cause of limb-girdle muscular dystrophy type 2L (LGMD2L). It is an autosomal recessive degenerative myopathy characterized by proximal weakness, weakness of the hip and shoulder girdles and prominent asymmetrical quadriceps femoris and biceps brachii atrophy. Defects in ANO5 are the cause of miyoshi muscular dystrophy type 3 (MMD3). It is a late-onset muscular dystrophy characterized by distal muscle weakness of the lower limbs, calf muscle discomfort and weakness, quadriceps atrophy. Muscle weakness and atrophy may be asymmetric. Belongs to the anoctamin family.

Protein type: Membrane protein, multi-pass; Transporter; Transporter, ion channel; Membrane protein, integral; Channel, chloride

Chromosomal Location of Human Ortholog: 11p14.3

Cellular Component: endoplasmic reticulum membrane; integral to membrane; plasma membrane; intracellular; vesicle

Molecular Function: intracellular calcium activated chloride channel activity

Biological Process: chloride transport; transmembrane transport

Disease: Gnathodiaphyseal Dysplasia; Muscular Dystrophy, Limb-girdle, Type 2l; Miyoshi Muscular Dystrophy 3